AGP Executive Report
Last update: 6 hours agoSleep Research: A major review found too little reliable evidence to show medical cannabis improves insomnia, sleep quality, sleep duration or daytime functioning, challenging its growing use as a sleep aid. Product Safety: The American Medical Association urged the FDA to apply rigorous drug-safety standards to botanical products, including cannabis, with clinical trials and post-market monitoring. Patient Access: UK artist Louis Petit, whose seizures were controlled with cannabis oil in the Netherlands, still cannot get an NHS prescription; the bankruptcy of the oil’s producer may further threaten his access. Federal Policy: The DEA has registered more than 900 medical cannabis dispensaries, a move that could bring federal protections and tax benefits to businesses. CBD and Hemp Rules: New hemp regulations are raising concerns for Vermont CBD producers and could push some THC products off shelves.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
